Stereotaxis, Inc. (NASDAQ: STXS) announced today that the results of the Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France on Sunday, August 28.
The STOP-VT study is the first-ever, prospective multicenter evaluation of magnetic navigation for VT ablation. The trial, led by Assoc. Prof. Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at the Na Homolce Hospital in Prague, Czech Republic was conducted at four of the world’s most prominent arrhythmia treatment centers, including, Hospital of the University of Pennsylvania, Indiana University School of Medicine, and Na Homolce Hospital, University of Leipzig. Fifty-three patients with previous severe heart disease were treated with ventricular tachycardia (VT) with the Stereotaxis Robotic Ablation System. The acute success rate in the study was an impressive 94 percent, and no patients suffered a major complication. The acute success results obtained from the STOP-VT study are 10-15 percent higher than similar published studies using conventional ablation techniques.
“VT is one of the most challenging arrhythmia facing electrophysiologists due to complex anatomy, the sensitive nature of ventricular tissue, and potentially lethal outcomes,” said Prof Neuzil. “ Catheter ablation of VT, one of the fastest growing EP procedures globally, requires the delivery of robust lesions for clinical success. The main advantage of Stereotaxis for treatment of ventricular tachycardia is the precise mapping and identification of the critical diseased portions of the heart that allows physicians to perform ablation in a more effective way. The results of the trial exceeded our expectations, both in terms of acute outcomes as well as overall safety.”
Prof Neuzil presented the STOP-VT data at ESC 2011 on Sunday, August 28. Due to the significance of the study, Prof Neuzil also discussed the study at an ESC press conference on Monday, August, 29, “Arrhythmias in the Real World.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts